Hemagglutinin 5 (H5) - Pipeline Review, H1 2016

  • ID: 3802753
  • Report
  • 53 pages
  • Global Markets Direct
1 of 5
Hemagglutinin 5 (H5) - Pipeline Review, H1 2016

Summary

‘Hemagglutinin 5 (H5) - Pipeline Review, H1 2016’, provides in depth analysis on Hemagglutinin 5 (H5) targeted pipeline therapeutics.

The report provides comprehensive information on the Hemagglutinin 5 (H5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hemagglutinin 5 (H5) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hemagglutinin 5 (H5)
- The report reviews Hemagglutinin 5 (H5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hemagglutinin 5 (H5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hemagglutinin 5 (H5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hemagglutinin 5 (H5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemagglutinin 5 (H5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Hemagglutinin 5 (H5) Overview

Therapeutics Development

Hemagglutinin 5 (H5) - Products under Development by Stage of Development

Hemagglutinin 5 (H5) - Products under Development by Therapy Area

Hemagglutinin 5 (H5) - Products under Development by Indication

Hemagglutinin 5 (H5) - Pipeline Products Glance

Early Stage Products

Hemagglutinin 5 (H5) - Products under Development by Companies

Hemagglutinin 5 (H5) - Products under Development by Universities/Institutes

Hemagglutinin 5 (H5) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemagglutinin 5 (H5) - Companies Involved in Therapeutics Development

Altravax, Inc.

Ilyang Pharmaceutical Co., Ltd

Inovio Pharmaceuticals, Inc.

NewLink Genetics Corporation

Vaxine Pty Ltd

Hemagglutinin 5 (H5) - Drug Profiles

DPC-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H5N1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IY-7640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3400X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemagglutinin 5 (H5) - Dormant Projects

Hemagglutinin 5 (H5) - Featured News & Press Releases

Sep 06, 2012: Inovio Pharma Takes Major Stride Toward Universal Influenza Vaccine

Jul 10, 2012: Inovio Pharma Initiates Phase I H1N1 Universal Influenza Vaccine Clinical Trial

May 16, 2012: Inovio Pharma's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial

May 16, 2012: Inovio's Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial

Mar 26, 2012: Inovio Receives US Patent For SynCon H1N1 Influenza Universal Vaccine

Jan 31, 2012: Inovio Pharmaceuticals Moves Closer To Universal Influenza Vaccine By Demonstrating Protective Immune Responses Against Multiple H3N2 And Type B Strains In Animal Studies

Nov 17, 2011: Inovio's Synthetic Avian Flu Vaccine Demonstrates Inhibition Of Multiple H5N1 Strains In Phase I Trial

Jul 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine

Jul 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial

Sep 30, 2010: About Inovio's SynCon Universal Influenza Vaccines

Sep 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award

Jun 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial

Mar 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine

Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies

Nov 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 53List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Altravax, Inc., H1 2016

Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016

Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Pipeline by NewLink Genetics Corporation, H1 2016

Pipeline by Vaxine Pty Ltd, H1 2016

Dormant Projects, H1 2016 36List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Hemagglutinin 5 (H5) Hemagglutinin-5 is a viral protein. It binds to sialic acid-containing receptors on the cell surface. This attachment induces virion internalization of through clathrin-dependent endocytosis and through a clathrin- and caveolin-independent pathway. It plays a major role in the determination of host range restriction and virulence.

Hemagglutinin 5 (H5) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 3 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

The author's latest report Hemagglutinin 5 - Pipeline Review, H1 2016, outlays comprehensive information on the Hemagglutinin 5 (H5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hemagglutinin 5 (H5) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Altravax, Inc.
Ilyang Pharmaceutical Co., Ltd
Inovio Pharmaceuticals, Inc.
NewLink Genetics Corporation
Vaxine Pty Ltd
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll